1.1
Apremilast, alone or in combination with disease-modifying antirheumatic drugs (DMARDs), is recommended as an option for treating active psoriatic arthritis in adults only if:
-
they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and
-
their disease has not responded to adequate trials of at least 2 standard DMARDs, given either alone or in combination and
-
the company provides apremilast with the discount agreed in the patient access scheme.